Sarah Gilbert | |
---|---|
Born | April 1962 (age 62) Kettering, Northamptonshire, England |
Alma mater | University of East Anglia (BSc) University of Hull (PhD) |
Known for | Vaccinology |
Children | 3 |
Awards | Albert Medal (2021) Princess of Asturias Award (2021) King Faisal Prize (2023) |
Scientific career | |
Fields | Vaccines[1] |
Institutions | University of Oxford Vaccitech Delta Biotechnology Leicester Biocentre Brewing Industry Research Foundation Christ Church, Oxford |
Thesis | Studies on lipid accumulation and genetics of Rhodosporidium toruloides (1986) |
Doctoral advisor | Colin Ratledge, Dr M. Keenan |
Website | www |
Dame Sarah Catherine Gilbert DBE FRS (born April 1962) is an English vaccinologist who is a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech.[2][3][4][5][6] She specialises in the development of vaccines against influenza and emerging viral pathogens.[7] She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011.
In January 2020, she read a report on ProMED-mail about four people in China suffering from a strange kind of pneumonia of unknown origin in Wuhan.[8] Within two weeks, a vaccine had been designed at Oxford against the new pathogen, which later became known as COVID-19.[9] On 30 December 2020, the Oxford–AstraZeneca COVID-19 vaccine she co-developed with the Oxford Vaccine Group was approved for use in the UK.[10] More than 3 billion doses of the vaccine were supplied to countries worldwide.[11]
gs
was invoked but never defined (see the help page).lancet
was invoked but never defined (see the help page).{{cite book}}
: CS1 maint: location missing publisher (link)